Cargando…

Reported adverse events related to use of hepatitis C virus direct-acting antivirals with opioids: 2017–2021

INTRODUCTION: Due to concerns over potential interactions between some hepatitis C direct-acting antivirals (DAAs) and opioids, we describe adverse event (AE) reports of concomitant use of opioids and DAAs. METHODS: AEs reported (July 28, 2017–December 31, 2021) with the administration of the DAAs g...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martinez, Anthony, Khan, Tipu, Dylla, Douglas E., Marcinak, John, Collins, Michelle, Saget, Brad, Conway, Brian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10544489/ https://www.ncbi.nlm.nih.gov/pubmed/37779203 http://dx.doi.org/10.1186/s12954-023-00874-y

Ejemplares similares

Assessment of Drug–Drug Interaction Risk Between Intravenous Fentanyl and the Glecaprevir/Pibrentasvir Combination Regimen in Hepatitis C Patients Using Physiologically Based Pharmacokinetic Modeling and Simulations
por: Mukherjee, Dwaipayan, et al.
Publicado: (2023)

Uptake of hepatitis C direct-acting antiviral treatment in China: a retrospective study from 2017 to 2021
por: Du, Xinyu, et al.
Publicado: (2023)

Incidence of depression in patients with hepatitis C treated with direct-acting antivirals
por: Egmond, Elfi, et al.
Publicado: (2019)

Analysis of death cases in Shenyang City, China, for immunization adverse event surveillance, 2009-2021
por: Gao, Dongmei, et al.
Publicado: (2023)

Curative Effects for B-Cell Lymphoma Accomplished by Direct-Acting Antiviral Agents of Hepatitis C
por: Hattori, Nobuhiro, et al.
Publicado: (2017)

Concomitant Treatment of Chronic Hepatitis C With Direct-Acting Antivirals and Multidrug-Resistant Tuberculosis Is Effective and Safe
por: Melikyan, Nara, et al.
Publicado: (2021)

Perceived physical health outcomes of direct-acting antiviral treatment for hepatitis C: a qualitative study
por: Goutzamanis, Stelliana, et al.
Publicado: (2021)

Adherence to opioid agonist therapy predicts uptake of direct-acting antivirals in people who use drugs: results from the French national healthcare database (the ANRS FANTASIO study)
por: Rolland, Benjamin, et al.
Publicado: (2022)

Crushing and Splitting Direct-Acting Antivirals for Hepatitis C Virus Treatment: A Case Series and Literature Review
por: Whelchel, Kristen, et al.
Publicado: (2021)

Global adverse events reported for direct-acting antiviral therapies for the treatment of hepatitis C: an analysis of the World Health Organization VigiBase
por: Hayes, Kaleen N., et al.
Publicado: (2021)

Geospatial Analysis of Opioid Dispensing Patterns in California: A 2021 Real-World Study
por: Lu, Hongxia, et al.
Publicado: (2023)

Transjugular Intrahepatic Portosystemic Shunt: A Possible Risk Factor for Direct‐Acting Antiviral Treatment Failure in Patients With Hepatitis C?
por: Piecha, Felix, et al.
Publicado: (2019)

Escalation of Opioid Withdrawal Frequency and Subsequent AMA Rates in Hospitalized Patients From 2017 to 2020
por: Horton, Terry, et al.
Publicado: (2022)

Descriptive Data on Trends Among Patients Hospitalized With Lyme Disease in Southwest Michigan, 2017–2021
por: Avner, Benjamin S
Publicado: (2022)

Incidence and Impact of Persistent Viremia on SVR Rates in Patients Receiving Direct-Acting Antiviral Therapy
por: Carver, Alicia B, et al.
Publicado: (2020)

Variation in adverse drug events of opioids in the United States
por: Liu, Edward Y., et al.
Publicado: (2023)

Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017
por: Aas, Christer F., et al.
Publicado: (2020)

Concomitant Treatment of Hepatitis C Virus and Diffuse Large B-Cell Lymphoma with Direct-Acting Antivirals in HIV Coinfection: A Case Report
por: Gallipani, Alyssa, et al.
Publicado: (2019)

The Effectiveness and Safety of Direct-Acting Antivirals in the Treatment of Hepatitis C Virus in Saudi Arabia: A Nationwide Study Based on the Saudi Ministry of Health Surveillance Data From 2017 to 2021
por: AL-Ahmari, Tasneem S., et al.
Publicado: (2023)

Evaluating imbalances of adverse events during biosimilar development
por: Vana, Alicia M., et al.
Publicado: (2016)

Liver Cirrhosis as a Risk Factor for Direct-Acting Antiviral Therapy Failure in Real-Life Hepatitis C Virus/Human Immunodeficiency Virus Coinfection
por: Boesecke, Christoph, et al.
Publicado: (2017)

Topiramate-related adverse events: Pattern and signals in the Korea Adverse Event Reporting System, 2010-2017
por: Choi, Junyeong, et al.
Publicado: (2020)

Disparities in mobile phone use among adults with type 2 diabetes participating in clinical trials 2017–2021
por: Nelson, Lyndsay A, et al.
Publicado: (2022)

Immune-related adverse events and the balancing act of immunotherapy
por: Conroy, Michael, et al.
Publicado: (2022)

Adverse events following yellow fever vaccination in immunocompromised persons
por: Lara, Amanda Nazareth, et al.
Publicado: (2021)

Adverse Events and Serological Responses After SARS-CoV-2 Vaccination in Individuals With Inflammatory Bowel Disease
por: Markovinović, Ante, et al.
Publicado: (2023)

Positive rates for Enterobius vermicularis eggs among preschool children in Yeosu-si, Jeollanam-do, Korea (2017–2021)
por: Lee, Myoung-Ro, et al.
Publicado: (2023)

Hepatitis C Virus Relapse After Ultrashort Direct-Acting Antiviral Therapy Associates With Expression of Genes Involved With Natural Killer-Cell and CD8(+) T-Cell Function
por: Orr, Cody, et al.
Publicado: (2021)

Underutilization of Hepatitis C Virus Seropositive Donor Kidneys in the United States in the Current Opioid Epidemic and Direct-Acting Antiviral Era
por: Li, Andrew A., et al.
Publicado: (2018)

Short-term Adverse Events With BIC/FTC/TAF: Postmarketing Study
por: Hayes, Edwin, et al.
Publicado: (2020)

Ocular Adverse Events after Inactivated COVID-19 Vaccination in Xiamen
por: Chen, Xiuju, et al.
Publicado: (2022)

Neutrophil Counts in Healthy South African Infants: Implications for Enrollment and Adverse Event Grading in Clinical Trials in an African Setting
por: Koen, Anthonet, et al.
Publicado: (2019)

Opioid Therapy Pharmacogenomics for Noncancer Pain: Efficacy, Adverse Events, and Costs
por: Xu, Yan, et al.
Publicado: (2013)

Mining reported adverse events induced by potential opioid-drug interactions
por: Chen, Jinzhao, et al.
Publicado: (2020)

Analysis of Opioid-Related Adverse Events in Japan Using FAERS Database
por: Hirai, Risako, et al.
Publicado: (2023)

Improving patient safety via automated laboratory-based adverse event grading
por: Niland, Joyce C, et al.
Publicado: (2011)

Adverse Events after Inappropriate In-Home Ultraviolet Phototherapy: Sunburn and Exacerbation of Psoriasis
por: Park, Jong Seo, et al.
Publicado: (2019)

Low Adherence Achieves High HCV Cure Rates Among People Who Inject Drugs Treated With Direct-Acting Antiviral Agents
por: Norton, Brianna L, et al.
Publicado: (2020)

Increasing national trend of direct-acting antiviral discontinuation among people treated for HCV 2016–2021
por: Carson, Joanne, et al.
Publicado: (2023)

New legislation, new frontiers: Indian psychiatrists' perspective of the mental healthcare act 2017 prior to implementation
por: Duffy, Richard M., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ij00ruoe13kphehgd6mf7lbki5